Karyopharm Therapeutics Inc KPTI:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 7:59 PM EST
11.11quote price arrow up+0.02 (+0.18%)
Volume
69,008
Close
11.09quote price arrow down-0.54 (-4.64%)
Volume
1,554,393
52 week range
10.57 - 25.98

...

Loading . . .

KEY STATS

  • Open11.66
  • Day High11.87
  • Day Low11.07
  • Prev Close11.63
  • 52 Week High25.98
  • 52 Week High Date04/23/20
  • 52 Week Low10.57
  • 52 Week Low Date03/05/21
  • Market Cap827.65M
  • Shares Out74.63M
  • 10 Day Average Volume2.52M
  • Dividend-
  • Dividend Yield-
  • Beta0.43
  • 1 Year % Change-55.68

RATIOS/PROFITABILITY

  • EPS (TTM)-2.73
  • P/E (TTM)-4.06
  • Fwd P/E (NTM)-4.61
  • EBITDA (MRQ)-170.878M
  • ROE (MRQ)-391.29%
  • Revenue (MRQ)108.09M
  • Gross Margin (MRQ)97.50%
  • Net Margin (MRQ)-181.59%
  • Debt To Equity (MRQ)377.91%

EVENTS

  • Earnings Date05/03/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Karyopharm Therapeutics Inc News

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Karyopharm Therapeutics Inc. is an oncology-focused pharmaceutical company. The Company is focused on the discovery, development, and commercialization of drugs directed against nuclear export and related targets for the treatment of cancer and other diseases. Its selective inhibitor of nuclear export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Its lead compound, XPOVIOTM (selinexor), received accelerated approval from...
Michael Kauffman M.D., Ph.D.
Chief Executive Officer
Sharon Shacham Ph.D.
President
Michael Mason CPA
Chief Financial Officer
Christopher Primiano J.D.
Executive Vice President
Tanya Lewis
Executive Vice President
Address
85 Wells Ave
Newton Center, MA
02459-3298
United States